Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid …
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid …
Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
NEW YORK and LONDON, March 4, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
Akari Therapeutics, Plc Announces Private Placement
NEW YORK and LONDON, February 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative …
[Read more...] about Akari Therapeutics, Plc Announces Private Placement
Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which …
